NCT06416735View on ClinicalTrials.gov

Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

July 20, 2020

Study Completion Date

July 20, 2020

Conditions
Hypertension EssentialSalt ExcessGenetic Hypertension
Interventions
DRUG

Amiloride

administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours

Trial Locations (1)

20132

San Raffaele Hospital, Milan

All Listed Sponsors
lead

Ospedale San Raffaele

OTHER

NCT06416735 - Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant | Biotech Hunter | Biotech Hunter